|
Volcano Announces the Availability of Integrated Fractional Flow Reserve Technology on All Major Cardiovascular X-ray Angiography Systems
Availability Builds on the Success of the Expanding s5i Integrated Platform
|
 |
Doppler
Guide Wire,
measuring FFR inside
coronary artery
image courtesy of
Volcano Corporation |
|
March 27, 2009 -- San
Diego --
Volcano Corporation (Nasdaq: VOLC), a leader in the development,
manufacturing and sales of products for the diagnosis and treatment
of coronary and peripheral artery disease, today announced
the availability of its integrated Fractional Flow Reserve
(FFR) technology on all major cardiovascular x-ray systems.
Interest
in the use of FFR, a guidewire-based technology that helps
assess a lesion's severity, has increased significantly since
the release of the multi-center randomized FAME (FFR versus
Angiography for Multivessel Evaluation) data in late 2008
and publication in the New England Journal of Medicine in January
2009. |
FAME demonstrated that FFR-guidance in routine multi-vessel PCI resulted in
clinically-superior outcomes and reduced the composite of death, documented
myocardial infarction, and repeat revascularization by 30 percent at one year.
The study also demonstrated that these improved clinical outcomes were complemented
by significantly reduced cost to the hospitals involved in the trial.
Volcano's integrated FFR technology can be purchased as part of Volcano's s5i system, offering clinicians access to IVUS and FFR at the patient bedside. Volcano has relationships with each of the major cardiovascular x-ray companies to facilitate the installation of the s5i with integrated FFR in any cath lab.
Joe Burnett, Vice President of Marketing at Volcano commented, "As
demonstrated by Volcano's FFR growth of 36 percent in Q4 2008 versus Q4 2007,
physicians are increasingly relying on FFR to help guide PCI procedures turning
to Volcano's s5i system as their preferred FFR solution. We are pleased to offer
customers the ability to have integrated FFR in their lab, regardless of the
x-ray system that they use."
Volcano's integrated s5i will be on display at the 2009 ACC meeting in Orlando at the company's booth as well as in the booths of GE, Philips, Siemens and Toshiba.
About Volcano
Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to
facilitate endovascular procedures, enhance the diagnosis of vascular and structural
heart disease and guide optimal therapies. The company's intravascular ultrasound
(IVUS) product line includes ultrasound consoles that can be integrated directly
into virtually any modern cath lab. Volcano IVUS offers unique features, including
both single-use phased array and rotational IVUS imaging catheters, and advanced
functionality options, such as VH® IVUS tissue characterization and ChromaFlo®.
Volcano also provides functional measurement (FM) consoles and single-use pressure
and flow guide wires and is developing a line of ultra-high resolution Optical
Coherence Tomography (OCT) and Forward Looking IVUS systems and catheters. Currently,
more than 4,000 Volcano IVUS and FM systems are installed worldwide, with approximately
half of its revenues coming from outside the United States. For more information,
visit the company's website at http://www.volcanocorp.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995. Any statements in
this release regarding Volcano's business that are not historical facts may be
considered "forward-looking statements," including statements regarding the company's
financial guidance for 2009, market adoption of the company's technology, the
impact of clinical and other technical data, the success and timing of product
development, product introduction and clinical trial programs, growth strategies
and market development and product sales. Forward-looking statements are based
on management's current preliminary expectations and are subject to risks and
uncertainties, which may cause Volcano's results to differ materially and adversely
from the statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from the results predicted are detailed
in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and
other filings made with the Securities and Exchange Commission. Undue reliance
should not be placed on forward-looking statements, which speak only as of the
date they are made. Volcano undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated events.
Source: Volcano Corporation
|
